Introduction
Vitamin D 3 (VD) is a lipophilic hormone essential for normal bone structure and maintenance of serum calcium (1) . VD action is mediated through the vitamin D receptor (VDR) (2) , a member of the steroid/thyroid receptor superfamily of ligand-regulated transcription factors (3, 4, 5) . This superfamily includes receptors for steroids such as progesterone, androgens, estrogens, glucocorticoids and mineralocorticoids, receptors for non-steroid hormones like vitamin D, thyroid hormones, all-trans retinoic acid and 9-cis retinoic acid as well as orphan receptors for which the ligand is unknown. VDR and other non-steroid receptor members of the superfamily form heterodimers with the retinoid X receptor (RXR), the receptor for 9-cis retinoic acid. In most cases, the VDR/RXR heterodimer binds VD response elements (VDREs) to mediate the biological activities of VD through transcriptional activation or repression of target genes containing VDREs in their regulatory sequence. In response to VD Materials pHG45-HC (30) , pCMV45 and pCMVAS45 (31) , pCMVgal (32), p91023B-VDR (2, 33), pCMX-RXRβ (34) and p23 containing rat 24-hydroxylase promoter in pMAMMneoLuc (35) have been described previously. pGL3-promoter, pGL3-basic and pGL3-control vectors were from Promega (Madison, WI). Mouse embryo fibroblasts (MEFs) from wild type and GADD45-null mice have been described (36) . 1,25D 3 was from Calbiochem (La Jolla, CA).
Baculovirus-expressed human VDR protein, human RXRβ protein and anti-RXRβ antibody were from Affinity BioReagents Inc. (Golden, CO). Anti-VDR antibody was from Chemicon International (Temecula, CA). Anti-Flag M2 and anti-β-actin antibodies were from Sigma (St.
Louis, MO). Anti-GADD45 (C-20), anti-cdc2 and anti-cyclin B1 (D11) antibodies were from Santa Cruz Biotech (Santa Cruz, CA). All oligonucleotides were synthesized by Invitrogen (Carlsbad, CA). Their sequence is available from W.B. on request.
Cell growth, flow cytometry and statistical analyses
To measure cell growth, OVCAR3 cells were plated in 96-well plates and treated with 1.25VD or ethanol vehicle (ETOH). Colorimetric methylthiazole tetrazolium (MTT) assays were performed as described (37) . OD 595 was read on a MRX microplate reader (DYNEX Technologies, Chantilly, VA). For each data point, eight samples were analyzed and the experiment reproduced three times.
To determine the cell cycle distribution, cells were fixed with 70% ethanol, stained with 50 µg/ml propidium iodide and analyzed on a FACScan (Becton Dickinson, Mountain View, CA). For each data point, duplicate samples were analyzed and the experiment reproduced three times. For cell growth and cell cycle analyses, statistical analysis was performed using the independent-samples t test. P< 0.05 was considered to be statistically significant.
Northern blot analysis and Gel mobility shift assay (EMSA)
To determine the level of GADD45 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA, Northern blot was performed as described (38) . EMSA was performed as described (32, 39) with modifications. Briefly, double-stranded oligonucleotides were endlabeled with 32 P using a T4 polynucleotide kinase labeling system (Life Technologies, Rockville, MD). 1 µl of radiolabeled probe (roughly 50,000 cpm) was mixed with 19 µl DNA binding reaction mixture that contains 250 ng VDR and 250 ng RXR in 10 mM Tris-Cl (pH7.9), 100 mM KCl, 0.1 mM EDTA, 15% glycerol, 100 µg/ml poly(dI:dC), 0.1 µg/µl bovine serum albumin, 1 mM DTT and 10 -7 M 1,25VD. The mixture was incubated at room temperature for 30 minutes.
For competition experiments, VDR/RXR was pre-incubated with 2 µg anti-RXRβ, anti-Flag M2 antibody or excess amount of cold probes on ice for 20 minutes before the EMSA reaction. The reaction mixture was resolved in a 5% non-denaturing polyarylamide gel and protein-oligo complexes were revealed by autoradiography. 7 was generated by digesting GADDLuc with BglΙΙ and EcoRΙ, filling with Klenow fragments and religation. Luc5 was generated by sub-cloning into pGL3-promoter vector at KpnΙ and BglΙΙ sites a 777 bp fragment released from Luc2 with KpnΙ and BamHΙ.
Site-directed mutagenesis was performed as described (40) using QuikChange Sitedirected Mutagenesis kit (Stratagene, La Jolla, CA). The sequence of all mutant constructs was verified by DNA sequencing.
Transcriptional analysis
For transfection studies, OVCAR3 cells were plated in 15% FBS RPMI 1640 medium at Lipofectamine. 4 hrs post-transfection, cells were treated with 1,25VD or vehicle in fresh medium for 36 hrs. Cells were harvested and luciferase and β-galactosidase (β-gal) assays were performed as described (40, 41) .
Chromatin Immunoprecipitation (CHIP) assays
For CHIP assays, OVCAR3 cells were treated with ETOH or 10 -7
Immunoblotting analysis and In vitro immunocomplex kinase assays
Immunoblotting analysis of GADD45 protein was performed as described (38) .
Immunoblotting analysis of cdc2, cyclinB1, VDR and β-actin was performed similarly as for GADD45 except that the cell extracts were prepared in buffer containing 20 mM Tris-Cl (pH 7.5), 300 mM NaCl, 3 mM EDTA, 3 mM EGTA, 100 µM Na 3 VO 4 , 1% NP-40, and protease inhibitor cocktail.
In vitro immunocomplex kinase assays were performed as described (42) with minor modifications. In brief, cellular extracts were prepared in buffer containing 20 mM Tris-Cl (pH 7.5), 300 mM NaCl, 3 mM EDTA, 3 mM EGTA, 100 µM Na 3 VO 4 , 1% NP-40, protease inhibitor cocktail and immunoprecipitated with anti-cyclin B1 antibody. Kinase assays were performed at Reactions were terminated by adding 2 × SDS-PAGE sample buffer. Samples were analyzed on a SDS-PAGE and the phosphorylated histone H1 visualized by autoradiography.
Establishment of stable clones from OVCAR3 cells
OVCAR3 cells were transfected with 10 µg pCMVAS45 plasmid and 0.5 µg pcDNA3
for the establishment of GADD45 anti-sense stable clones or with pcDNA3 alone for the Vector-OVCAR3 controls. For the establishment of stable clones with GADDLuc reporter, OVCAR3 cells were transfected with 10 µg GADDLuc plasmid and 0.5 µg pcDNA3. All stable clones were obtained through selection with 100 µg/ml G418 for a period of about 4 weeks and clonal isolation with glass cylinders.
Results

1,25VD suppresses OCa cell growth and induces cell cycle arrest at G1/S and G2/M
To better understand the molecular mechanism of VD action in OCa cells, we tested the response of OCa cells to 1,25VD in proliferation assays. The cells were treated with vehicle or 10 -7 M 1,25VD for 6 or 9 days and cell growth was analyzed by MTT assays. As shown in was estimated as 13% while the percentage of cells at G2/M increased by 8% (Fig. 1C ),
suggesting that cell cycle arrest at both checkpoints contributed roughly equally to the growthsuppressing activity of 1,25VD. At variance with drugs used in conventional cancer chemotherapy, inhibition of cancer cell growth by 1,25VD is a chronic process, explaining why the effect on the cell cycle is modest and requires treatment for a longer time.
GADD45 is a primary and immediate early response gene for 1,25VD in OCa cells
To identify the genes that mediate the inhibitory effects of 1,25VD on cell cycle progression, a preliminary microarray analysis was performed to screen for genes that are Fig. 2A) , showing that the induction of GADD45 mRNA by 1,25VD is dose-dependent. The induction was detectable as early as 2 hrs following 1,25VD treatment with maximum induction detected at 8 hrs ( To define the specific DNA elements that mediate the induction of GADD45 by 1,25VD, the genomic sequence of GADD45 was examined for the presence of putative VDREs. Based on similarity to the consensus VDRE sequence (46) and the VDRE sequence of known VD target genes, such as osteopontin (OPN) (47) and osteocalcin (OC) (48) , five putative DR3-type VDREs were identified (Fig. 3A ). Four were in introns, one in exon 4 but none in the 5' promoter region.
To test which of the five putative VDREs bind the receptors, EMSAs were performed with recombinant VDR and RXR proteins. As shown in Figure To test whether 1,25VD regulates the GADD45 reporter through VDR, the activation of the reporter was tested in HeLa cells that lack functional VDR. As shown in Figure To determine which of the putative VDREs is functional, OVCAR3 cells were transfected with reporter constructs where VDREs, either individually or in combination, were deleted or mutated by altering key nucleotides known to be essential for receptor interaction. As shown in Figure 6 , panel A, deletion of the VDRE-A or VDRE-A plus VDRE-B region did not affect the induction. Deletion into the VDRE-D region caused a significant decrease while further deletion into the VDRE-E region eliminated the induction. These analyses suggest that regions around VDRE-D and VDRE-E are essential for regulation of GADD45 by 1,25VD.
Site-directed mutation in VDRE-E eliminated the induction, while single or multiple mutations of key nucleotides in the intronic VDREs had no effect. This suggests that only VDRE-E is essential for the induction. This conclusion is consistent with the lack of the induction in mutant reporters containing only VDRE-D or both VDRE-A and VDRE-B (Fig.   6A ). It is also consistent with the induction of the reporter that contains only VDRE-E (Luc3) and with the loss of this induction by site-directed mutation of VDRE-E (MTELuc3) (Fig. 6A ).
Individual mutation of the first two VDREs or combined mutation of all first three
VDREs actually increased the induction by 1,25VD, indicating that some VDREs may function in a negative fashion. The deletion of the VDRE-D region, not the mutation of the VDRE-D sequence, caused a decrease in the induction, suggesting that DNA elements in the VDRE-D region for transcription factors other than VDR may cooperate with VDR/RXR binding to VDRE-E to mediate the up-regulation of GADD45. The lack of a VD effect on the activity of pGL3-basic, pGL3-promoter and the pGL3-control vectors indicates that the regulation of the reporters by 1,25VD is specific to the GADD45 sequence.
To demonstrate that the VDRE-E interacts with VDR in vivo, OVCAR3 cells were treated with or without 1,25VD and CHIP assays were performed with anti-VDR antibodies ( To test whether GADD45 mediates the inhibitory effect of 1,25VD on OCa cell cycle progression, OVCAR3 cells were stably transfected with an expression vector containing GADD45 cDNA in the anti-sense orientation (31) or an empty vector. Immunoblot analysis of GADD45 was used to select stable clones with significantly reduced level of GADD45 protein by the anti-sense GADD45 as compared to the control clones (Fig. 7B) . Although the anti-sense GADD45 did not completely eliminate GADD45 protein (Fig. 7B) , it decreased the expression of GADD45 protein in the presence of 1,25VD to a level lower than basal level of control clones (Fig. 7B) . In other words, the anti-sense clones represent a functional "knock out" of GADD45 in terms of the induction by 1,25VD. 
GADD45 mediates 1,25VD-induced decrease in Cdc2 kinase activity in OCa cells
It is well established that the G2/M transition of mammalian cells is controlled by the M phase promoting factor, a heterodimeric complex between cdc2 and cyclin B. Studies in recent years suggest that GADD45 may directly regulate the activation of cdc2 kinase (29) . Therefore, the effect of 1,25VD on cdc2 kinase activity in control and GADD45 anti-sense clones was measured by in vitro immunocomplex kinase assays. As shown in Figure 9 , 1,25VD decreased the kinase activity of cdc2 in the control clone. In the GADD45 anti-sense clones, there is an increase in cdc2 kinase activity (Fig. 9) , presumably due to the decrease in the level of GADD45
protein. More importantly, 1,25VD did not decrease the activity to a level below the basal activity of control clones. Immunoblot analysis showed that 1,25VD decreased the level of cyclin B protein and that the decrease was not observed in the anti-sense clones (Fig. 9 ), suggesting that GADD45 mediates the effect of 1,25VD on cdc2 activity by regulating the cyclin B level in OCa cells. The data clearly suggest that G2/M arrest induced by 1,25VD in OCa cells is mediated through GADD45 and a subsequent decrease in cdc2 kinase activity.
Discussion
GADD45 is a nuclear protein that binds to numerous cellular proteins and plays a role in cell cycle progression as well as the maintenance of genomic stability. Our studies have identified GADD45 as one of the primary target genes for 1,25VD and suggest the following model of VD action in OCa cells (Fig. 10) . 1,25VD induces binding of the VDR/RXR heterodimer to the VDRE located in the fourth exon at a position downstream from the termination codon for protein translation. Presumably through the recruitment of co-activator complexes, the activated VDR/RXR interacts with Pol II complex bound to the promoter and increases the rate of GADD45 transcription. This leads to an increase in the amount of GADD45
protein that, through a yet unknown undefined mechanism, decreases the level of cyclin B, the regulatory subunit of cdc2 kinase. The resulting decrease in cdc2 activity is then responsible for disturbed cell cycle progression to M phase.
Induction of GADD45 can be detected in cells within 2 hrs after treatment with 1,25VD (Fig. 2B) . With the lack of VD effect on the mRNA stability (Fig. 2C ) and the identification of functional VDREs in the genome (Figs. 3-6 ), our data establish GADD45 as a primary and immediately early response gene for 1,25VD. Furthermore, our data suggest that GADD45
regulation is mediated through a VDR/RXR heterodimer, instead of a VDR/VDR homodimer.
This conclusion is reached based on the inability of VDR to bind to all putative VDREs in
EMSAs until the addition of RXR and the up-shift of the complexes by RXR antibody (Fig. 3 ).
At variance with the belief that nuclear receptors forming heterodimers with RXRs bind DNA in the absence of ligand, our CHIP assays ( Since the p53 in OVCAR3 cells is mutated (50), the regulation of GADD45 transcription by 1,25VD obviously occurs independently of p53 activity. This is consistent with the identification of the VDRE in the fourth exon that is distant from the p53 binding site in the third intron (30) . This is also consistent with the conclusion reached by a published study in squamous cell carcinoma (44). Furthermore, the regulation is also likely to be independent of BRCA1 since the DNA element for this tumor suppressor is located in the promoter region (51) . It is striking that four of the five putative VDREs bound VDR/RXR equally well in EMSAs, but only VDRE-E mediated the up-regulation of GADD45 reporter by 1,25VD. The other putative VDREs are either nonfunctional or may act in a negative way. Overall, the data suggest that the regulation of GADD45 by 1,25VD is a complex process that may involve the interaction of the receptor bound to the VDRE and other transcription factors. The different VDREs may also function in a cellspecific manner to mediate the regulation of GADD45 expression by 1,25VD.
To the best of our knowledge, known VDREs are located in the promoter region or the upstream regulatory sequence. It is unique that the specific VDRE that is functional in GADD45 induction is located in an exon and falls into the 3' un-translated region. The VDRE may provide a good model system to study how DNA response elements in the 3' end of the coding sequence regulate the transcription of a target gene via the Pol II complex bound to the promoter in the 5'
end. Recent studies suggest that site-specific transcription factors (52), including nuclear hormone receptors (53) , recruit components of the Pol II complex to the enhancer sequences and, after co-activator mediated chromatin remodeling, the adjacent nucleosome slides downstream for a certain distance to initiate transcription. It remains to be seen whether DNA response elements at the 3' end of the coding sequence recruit Pol II components and, if so, how the modified nucleosome moves to the right position to permit transcriptional initiation since this nucleosome has to either slide upstream for a significant distance or jump across the coding region to initiate transcription.
Our studies link GADD45 induction specifically to the inhibition by 1,25VD of cell cycle progression through the G2/M checkpoint. This linkage was established using cells in which Previous studies (45) have shown that the induction of GADD45 expression in squamous cell carcinoma by VD is associated with an increased interaction with PCNA. Although we have not examined the association of GADD45 with PCNA, it appears unlikely to be the case in OVCAR3 cells. PCNA is known to be required for DNA replication in S phase but our data show that G1/S arrest still occurs in OVCAR3 cells expressing the anti-sense cDNA of GADD45
( Fig. 7C and 7D) . Instead of PCNA, our studies show a 1,25VD-induced decrease in cdc2 activity, which is associated with a decrease in the level of cyclin B1 protein. The decrease was not observed in the stable clones expressing GADD45 anti-sense cDNA (Fig. 9) . The data suggest that GADD45 mediates the effect of 1,25VD on cdc2 activity. Our data concur with the proposed role of GADD45 in G2/M arrest induced by certain types of DNA damaging agents (28, 29) . Zhan et al. (29) have shown that GADD45 inhibits the interaction between cyclin B and cdc2. Later, it was shown that GADD45-induced cell cycle arrest at G2/M is associated with an altered cellular distribution of cyclin B1 (54), which seems to require a functional p53. Our conclusions, however, differ from the above studies since we detected a decrease in the level of cyclin B1 protein (Fig. 9) . As mentioned earlier, OVCAR3 cells contain a mutant p53 (50) .
Obviously, GADD45 exerts its effect on cdc2 activity and the G2/M transition in the OCa cells independently of p53. It remains to be determined whether the effect of 1,25VD on G2/M in OCa cells is exerted through GADD45 alone or in combination with another protein that functions similarly to p53.
Besides its role in regulating G2/M transition, GADD45 plays an essential role in DNA repair and in the maintenance of genomic stability. MEFs derived from GADD45-null mice exhibit aneuploidy, chromosomal abnormalities, gene amplification and centrosomal amplification (36) . GADD45-null mice display increased sensitivity to dimethylbenzanthraceneinduced carcinogenesis (43). It is intriguing that dimethylbenzanthracene increased female ovarian tumors more in GADD45-null mice compared to the wild type (43). GADD45 induction by 1,25VD through VDR suggests that VDR may act in a p53 independent tumor-suppressing pathway to affects ovarian genomic stability. Along this line, VDR has been shown to act as a bile acid sensor for the secondary bile acid lithocholic acid (LCA) (55), a potential enteric carcinogen that induces DNA strand breaks, forms DNA adducts and inhibits DNA repair enzymes. It is interesting to find out whether ovarian carcinogens or DNA-damaging processes (e.g. ovulation) activate VDR in ovarian epithelial cells and, if yes, whether the VD-independent VDR activation functions in DNA repair.
OCa is a fatal disease unless detected at early stages and the overall 5-year survival in patients with this malignancy is less than 40%. The poor response of advanced OCa to current treatments stimulates the search for novel therapeutic strategies. The present study provides a strong rationale for further investigation of 1,25VD along with the less calcemic synthetic VD analogues (56) as a chemo-preventive agent against OCa. Furthermore, half of OCa is estimated to lose p53 function, thus becoming refractory to drugs targeting p53 pathways. These tumors may however still be sensitive to synthetic VD since 1,25VD induces GADD45 in a p53-independent manner. 
